je.st
news
Immunocore completes $320 million (A 205 million) private financing round
2015-07-16 15:48:23| Biotech - Topix.net
Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor based biological drugs to treat cancer, viral infections and autoimmune disease, today announced the completion of a US $320 million private financing round. The oversubscribed round includes new investors, Woodford Investment Management, Malin Corporation plc, Eli Lilly and Company and RTW Investments, as well as a number of new and existing investors in Immunocore.
Tags: private
million
round
financing
Category:Biotechnology and Pharmaceuticals